Recent News

article

2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica

Jack Cush, MD

Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.

Dr. John Cush Tweet
@RheumNow
Beverages & relative risk of hyperuricemia (HUA) & gout. Metanalysis of 52 studies shows alcohol has signif high risk of gout (OR  1.8) & HUA (OR 1.5); & sugar-sweetened beverages (SSBs) incr gout (1.37) & HUA (1.48); as well as tea for HUA among female (OR = 1.29). Coffee https://t.co/nq1fKvOlgv
Dr. John Cush Tweet
@RheumNow
High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. (CDC https://t.co/wnPdEueb4N
Dr. John Cush Tweet
@RheumNow
Two crystals in one joint? Cryptococcus risk doubled with JAK inhibitors? And early damage in Sjögren’s linked to a 12–14-fold increase in lymphoma risk? Dr. Jack Cush breaks down the findings behind the numbers in this week's RheumNow roundup: - JAK inhibitors: Cryptococcal https://t.co/4RkznhyoIt
Dr. John Cush Tweet
@RheumNow
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c
Dr. John Cush Tweet
@RheumNow
Comorbidity management is subpar in Rheum. Surveys of 2213 inflamm rheum Dz pts & 140 rheumatologists. Rheums think theyre OK (71-92%) screening (HTN, OP, vaccines, CA), but pts say NOT (12=33%).Rheums agree they have no structured comorbidity screening in place (time 91%, https://t.co/mqcptziRdw
Dr. John Cush Tweet
@RheumNow
Impact of Myositis in Scleroderma Patients Systemic sclerosis (SSc) may have overlap features such as myositis. When present, myositis in SSc is associated with an increased risk of cardiac involvement and a shift in mortality away from ILD towards a greater cardiac risk. https://t.co/bKYP9FmadY

Video

Podcasts

  • Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
  • Double Trouble (10.23.2026)
  • Troubles with ‘Gut Feelings’
  • Don’t Hold the JAK (10.9.2026)
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Clinical dilemmas in axSpA and PsA

Sponsored by UCB
UCB October RX Update
Explore some of the challenges rheumatologists face in clinical practice, including expert perspectives from UCB's Annual International Immunology Summit.
Read Post

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie October RX Update
Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.
Read Post

Obesity – Inflammation – PsA

Sponsored by Lilly Medical Affairs
Lilly October
Learn about the inflammatory intersection between Psoriatic Arthritis and Obesity, and why adiposity is more than a comorbidity.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Rheumnow Survey

Vote
×